Vivimind: Forget About It

vivimindYou’ve seen the billboards for Vivimind across Canada. Remember them?  Targeting an aging population of boomers, Vivimind is touted as a “scientifically proven” natural health product that “protects memory function”. The website goes to great lengths to promote that Vivimind is both “scientific” and “evidence based”. So let’s take a look at what sort of science supports the claims for Vivimind.

What condition does Vivimind treat?

Vivimind is marketed to treat mild memory decline, also called “Age Associated Memory Impairment” (AAMI).  Sometimes called “late life forgetfulness,” AAMI is a common condition that appears to be part the normal aging process.[1] Common symptoms include brief memory lapses, and difficulty remembering names and words. These symptoms are considered mild, and do not impact on one’s professional or social life. It can worsen as one ages, but you’re still able to function normally. AAMI is unrelated to degenerative neurological diseases like Alzheimer’s disease.

AAMI is common, with some estimates of up to one in three being affected between the age of 60 to 78.[2] While AAMI is not a disease, various strategies have been proposed to help maintain active function, such as exercise, keeping an active social life, languages, and games. No comprehensive evaluation of these interventions has been done.

AAMI appears to be a consequence of an aging body. It’s not severe, it’s not a degenerative disease, and it doesn’t signal the onset of Alzheimer’s disease.

What’s in Vivimind?

The active ingredient in Vivimind is 3-amino-1-propanesulfonic acid, also known as tramiprosate or homotaurine.  The manufacturer of Vivimind claims that the it is “based on the naturally occurring ingredient homotaurine” and “identical chemically to natural homotaurine.” This clarifies that the actual chemical in Vivimind is synthetic: it’s manufactured in a laboratory, and not naturally sourced.

What does the science say?

Vivimind was once a promising prescription drug.  It was called Alzhemed, and was hoped to be a breakthrough treatment for Alzheimer’s disease. [3] Alzheimer’s disease is a neurodegenerative process, where amyloid plaques form in the brain, leading to dementia. It was proposed that Alzhemed might reduce the deposits of plaque, slowing progression of the disease.

A preliminary study examined Alzhemed in mild-to-moderate Alzheimer’s disease. [4] Researchers studied its safety, tolerability, and pharmacokinetics (how the drug behaves in the body), but not whether the drug worked. Overall, the study found that Alzhemed was generally well tolerated and appeared safe. There was evidence to show that it did reach the brain. This was encouraging enough to support further studies to answer the question: Does the drug actually work?

Two major phase 3 trials were subsequently launched to test if Alzhemed could be an effective treatment for Alzheimer’s disease. Unfortunately, the results showed that patients taking Alzhemed did no better than patients taking a placebo. [3] The FDA concluded that the results could not support a claim of clinical efficacy – that is, the manufacturer could not claim the drug worked.[5] A European trial of Alzhemed was subsequently discontinued before the results were reported.

Case closed for Alzhemed? Not quite. After the failure of the phase 3 trial, where Alzhemed was shown to be ineffective, the manufacturer announced its intention to bring the product to market – but not as a treatment for Alzheimer’s.  Nope – they were going after a bigger market – people with age associated memory impairment. And forget about all that pesky evidence and data the FDA wanted. Since approval of Alzhemed as a prescription drug to treat Alzheimer’s disease seemed out of the question, the manufacturer, Neurochem, decided to market it as a natural health product. [3] [6] The company changed  its name to Bellus Health, and renamed the product Vivimind.

With respect to AAMI, the currently marketed use for Vivimind, there are no published trials to demonstrate any positive effects. In fact, there are no published trials at all that have examined Vivimind for AAMI.  Recall that AAMI is considered a natural consequence of ageing. There is currently no medical reason to treat AAMI with any drug, and  there are no demonstrated biological changes of AAMI that could be impacted by Vivimind.

So the science tells us that Vivimind is a failed prescription treatment for Alzheimer’s disease, and there is no science to support its current claims for treating AAMI.

Questionable claims

The website for Vivimind states “VIVIMINDTM can help protect your brain cells during the normal course of aging”. The reference given for this statement, by Gervais et al, is not a clinical trial, and does not provide any evidence to support this statement. [7] Other statements are made about how Vivimind offers “Improved cognitive performance (remembering test instructions, verbal ability, language comprehension, planning and executing skills by 33% vs. placebo”  Sounds impressive. But the reference, sadly is “Data on file” –  likely the Alzheimer’s trial that failed to show Vivimind is better than a placebo.  In fact, the term “data on file” shows up frequently in the promotional material for Vivimind.  If the evidence is so persuasive, why hasn’t the manufacturer published it?

How safe is Vivimind?

According to their website,  Vivimind “is generally well tolerated at the recommended dose, some people may experience nausea, weight loss, dizziness or fainting.” The dosage of Vivimind is 1-2 tablets twice per day. No information is given (and no science exists) to tell you whether to take one tablet or two tablets at a time. However, based on the largest published trial, nausea and vomiting are more common when two tablets are taken twice per day.

No information is given about how long Vivimind should be taken. The published phase 2 trial followed patients for 17 months. There is no published data to demonstrate that Vivimind can be safely taken longer than this.

What do other groups think of Vivimind?

Here is the statement from the Alzheimer’s Association:

The Alzheimer’s Association does not support the use of the dietary supplement VIVIMIND – by people with Alzheimer’s disease or other dementia, family members of people with dementia, people worried about getting Alzheimer’s, or the general public.

At this time there is no statistically significant proof that VIVIMIND is an effective treatment for Alzheimer’s disease or any other related disorder. A Phase III clinical trial of the compound for Alzheimer’s disease failed – it showed no statistically significant benefit versus placebo for people with Alzheimer’s.

In addition there is no evidence of its claims to protect against memory loss, preserve the brain structures associated with memory and learning, or maintain mental skills and abilities in health individuals of any age.

Marketing such a product is not in the best interest of people with Alzheimer’s and their families, or the general public. It is misleading and exploits people who are worried and vulnerable.

Everyone wants better treatments for Alzheimer’s and dementia. However, proof of the value of all interventions – including medical treatments, lifestyle changes, and dietary supplement – must precede new products in the marketplace. This product does not have this proof.

This press release can be accessed here (PDF).

Here is the evaluation by the Centre for Science in the Public Interest:

The drug Alzhemed, doesn’t work. What to do? If you’re Bellus Health Inc. of Laval Quebec, you rename the drug Vivimind and launch it as “a new scientifically proven natural health product” that “protects memory function.”

You tell the public that your unpublished research found Vivimind  “to improve cognitive performance (verbal skills, memory, comprehensive ability, planning and execution skills) by 33% versus placebo.”

But you ignore the fact that Vivimind was tested only in Alzheimer’s patients, and that their mental skills deteriorated as quickly as those of Alzheimer’s patients who were given a placebo. [8]

So what’s the bottom line with Vivimind?

Vivimind could not meet the efficacy standard established for prescription drugs. It’s now marketed as a natural health product. There is no convincing evidence that it is an effective treatment for Alzheimer’s disease, Age Associated Memory Impairment, or any other medical condition.

What does this say about the regulatory system for Natural Health Products in Canada?

The marketing of Vivimind in Canada demonstrates that Canada’s regulatory framework is clearly incapable of protecting the health and safety of Canadians. It is astonishing that a drug that has been demonstrated in clinical trials to be ineffective can be subsequently sold in Canada – for an unrelated use and without any evidence – as a natural health product.

Vivimind demonstrates that there clearly two standards for health-related products in Canada: A high standard for prescription drugs and typical over-the-counter drugs, where evidence of efficacy and safety is required, and a seemingly non-existent one for anything marketed as a “natural health product”, where evidence of effectiveness clearly isn’t necessary.


Vivimind is available in Canada only because of a lax regulatory framework that has allowed an ineffective prescription drug to be rebranded and marketed as a natural health product.  Until data is published to show it is effective, there is no compelling reason for anyone to take Vivimind. Vivimind has no place in the science-based pharmacy, or in your medicine cabinet.

For More Information

Reference six by Mark Anderson provides an excellent overview of the saga of Neurochem, how it became Bellus Health, and how Alzhemed was rebranded to Vivimind.


[1] “Age Associated Memory Impairment” NYU Medical Center. (Accessed April 2, 2009)

[2] Koivisto K, Reinikainen KJ, Hänninen T et al. Prevalence of age-associated memory impairment in a randomly selected population from eastern Finland. Neurology 1995;Apr;45(4):741-7.

[3] “Alzhemed” from Alzforum: Drugs In Clinical Trials. (Accessed March 31, 2009).

[4] Aisen, P., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., & Garceau, D. (2006). A Phase II study targeting amyloid- with 3APS in mild-to-moderate Alzheimer disease Neurology, 67 (10), 1757-1763 DOI: 10.1212/01.wnl.0000244346.08950.64

[5] FDA Deems U.S. Alzhemed Trial Results Inconclusive. From Alzheimer Research Forum. (Accessed April 3, 2009) Available at:

[6] Anderson M. Just watch me. National Post. Tuesday, September 9, 2008. (Accessed March 31, 2009)  Available at:

[7] GERVAIS, F., PAQUETTE, J., MORISSETTE, C., KRZYWKOWSKI, P., YU, M., AZZI, M., LACOMBE, D., KONG, X., AMAN, A., & LAURIN, J. (2007). Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis Neurobiology of Aging, 28 (4), 537-547 DOI: 10.1016/j.neurobiolaging.2006.02.015

[8] No thanks for the memories. Nutrition Action Healthletter.  Centre for Science in the Public Interest April 2009, page 8.

13 thoughts on “Vivimind: Forget About It

  1. I started taking vivimind and actually was getting alzheimer like symptoms. Stopped immediately.
    why is health canada allowing this to be an over-the-counter optiion??

  2. Tramiprosate Ineffective in Alzheimer’s Disease

    More data on the clinical trial was published since I posted my article. This was published today:


    “There were no beneficial effects on tests of cognitive functioning or dementia,” said Paul Aisen, M.D., of Georgetown University Hospital, who presented the findings at a late-breaking session of the American Academy of Neurology meeting. “This was a negative trial.”

  3. Actually, this article is set tight on a completely biased, pre-concluded opinion and does NOT review all the evidence. Curious, how many “Science-based” people often fall into this trap. It’s truly ironic, especially when you don’t have the real facts, which I can’t cover in detail here. As Krishnamurti taught, a hard conclusion mentality closes the mind.

    Vivimind has been demonstrated to be effective, and now The Journal of Nutrition and Aging has published further human clinical trials proving such. Over 2,000 people have had an over 60% positive results better than placebo, in 15 years of trials. Where you get your information from, is beyond me. Over $300 million dollars would not have been invested in a false hope. Just because the FDA didn’t approve it, does not mean it was ineffective. The FDA is deeply flawed itself and under fire from many directions right now; let’s be circumspective. If you hold them as your standard, no wonder your conclusions are way off. Alzhemed was not approved because it missed the reproducible results in the stringent cognitive and memory re-testing by only a very small percentage, and thus refused the final approval. NOT because it was ineffective. So yes, they pursued the health products market, as anyone with something helpful that is still a viable business option, might do. Unorthodox and attention-raising perhaps, but not evil, as the writer unfortunately concludes. Just because something is failed as a drug, (which is a whole barrel of delusional concepts humanity has swallowed, and another topic), does not mean the substance *itself* is ineffective. And many drug manufacturers are shaking down the highest-quality, most effective natural supplement product suppliers right now, trying desperately to gain even more traction and global medicinal control, as people continue to wake up and support genuine alternatives. Dollars/Euros uber alles.

    To readers: Please do more research, and speak to the company itself; the internet allows huge opinions to gain coverage via search engine positioning and anyone to present themselves as arbiters of conclusions and facts. Granted, more research may need to be done and negative supporting opinions (key word) from different sources are presented here, which I will investigate further. But, I also use Vivimind, it works for me, and I know other people who are getting good results with it as well.

    • If there is any evidence to demonstrate homotaurine is effective for age-associated memory impairment, please cite your reference. Stringing a collection of conspiracy theories together does not comprise evidence. This blog is called science-based pharmacy, not anecdote-based pharmacy, for a reason.

      • Ok, so here’s what is happening with the evidence used by the manufacturer…

        The original RCT referenced in the medscape article from comment #4 is the Alphase trial. They looked at ADAS-cog and CDR-SB total scores, found no benefit at all. Nada,zip,zero.

        Now, here comes the questionable part. Some of the authors of the Alphase trial did a post-hoc analysis (PMID: 19536424) of a small 312 patient sub-group from the Alphase trial (who had undergone an MRI) and looked at their scores. They used tricky statistics: two models of analysis (Fixed and Mixed effect model I think…), one model showed no significant benefit in overall ADAS-Cog while the other found some improvement at certain times during the study.

        BTW, the 33% improvement in cognitive performance is not significant (p=0.098).

        So, they used a sub group of ALZHEIMER patients (not AAMI) from the original NEGATIVE trial to find some positive effects analysed after complicated calculations…This is the data that the manufacturer uses. It all seems cherry-picked data to me.

        Why did the authors bother to do a post-hoc analysis if the original data showed unequivical negative results? Maybe it could be that in those whose hippocampus atrophy was reduced may have better results, or because the study’s sponsors desperately wanted to recoup their losses by promoting this as a natural product. Jus’ sayin’.

    • wow,you’ve managed to bash this article the same way you state they are bashing Vivimind. You explicitly state to do more research and yet you don’t provide any links to anything worth reading.

      Thank you for this article. I was seriously considering taking this, but I have since decided that it may be better to stick to something natural. Flax Seed Oil, Cod Liver Oil, Omega 3…

  4. “…Speak to the comapny itself.”

    [Sarcasm Value = 1]

    Ah yes, speak to the people who are financially invested in the product. They of all parties could not possibly be biased by any result; and above all they are going to be the most objective about failing to reproduce results “by only a very small percentage.”

    [Sarcasm Value = 0]

    “I use Vivimind…” Oh… Do tell…?

    “It works for me.”

    Uh-huh. Apparently.

    ….Oh. Did I forget to turn the sarcasm back on again? Must find some way of bolstering my memory.

  5. My dad has been diagnosed with Alzheimers.

    I was desperate to hear that there was no cure. Then his Doctor suggested Vivimind, without any kind of ignorant sarcasm, it worked. My family and I couldn’t believe it.

    The person who is biased Mr. Kennedy Goodkey…is you.
    Your sarcasm is trully ignorance! We are all free to try what we want and to have an opinion about it. Or do we have to think what you think?
    There are also drugs which may work for some and not others…why are they on the market? Be indifferent about the drug…less ignorant.

    I just want people to know that for my family Vivimind is working with success…however long it may be for. Am happy that my dad can talk and think like he did before he got alzheimers.

  6. Pingback: Part Fills For May 1, 2010 « Science-Based Pharmacy

  7. i have been taking this product for six months……i dont have alzeimers or dementia….but i did have anxiety issue’s…..this product works….it makes you more more composed and calm ….no i dont suppose its strong enough to cure alzeimers….but i feel it could be a good preventive measure……

  8. Pingback: Dishonest Marketing And An Alt-Med Example | Meddling Kids

Comments are closed.